

David S Schade

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8101097/publications.pdf>

Version: 2024-02-01

35
papers

457
citations

1040056

9
h-index

752698

20
g-index

35
all docs

35
docs citations

35
times ranked

418
citing authors

#	ARTICLE	IF	CITATIONS
1	Resolving the Egg and Cholesterol Intake Controversy: New Clinical Insights Into Cholesterol Regulation by the Liver and Intestine. <i>Endocrine Practice</i> , 2022, 28, 102-109.	2.1	10
2	Prevention of Coronary Heart Disease: A Translational Clinical Challenge. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 11-23.	0.2	9
3	Extending Coronary Artery Calcium Scanning with CT Coronary Angiography in the Primary Care Setting. <i>American Journal of Medicine</i> , 2022, , .	1.5	0
4	Guidelines for the Prevention of Symptomatic Cardiovascular Disease, Based upon the Presence of Coronary Artery Calcified Plaque—Provided by the Society for the Prevention of Symptomatic Heart Disease. <i>World Journal of Cardiovascular Diseases</i> , 2022, 12, 320-341.	0.2	6
5	Stop Stenting; Start Reversing Atherosclerosis. <i>American Journal of Medicine</i> , 2021, 134, 301-303.	1.5	7
6	The Reply. <i>American Journal of Medicine</i> , 2021, 134, e585.	1.5	0
7	Should Routine Screening for Coronary Artery Disease Be Recommended? A Comparison With Routine Screening for Colon Cancer. <i>American Journal of Medicine</i> , 2020, 133, 155-157.	1.5	7
8	The Reply. <i>American Journal of Medicine</i> , 2020, 133, e324-e325.	1.5	0
9	An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 2478-2484.	8.6	19
10	The Reply. <i>American Journal of Medicine</i> , 2020, 133, e536-e537.	1.5	0
11	Cholesterol Review: A Metabolically Important Molecule. <i>Endocrine Practice</i> , 2020, 26, 1514-1523.	2.1	83
12	Risk Factors for First and Subsequent CVD Events in Type 1 Diabetes: The DCCT/EDIC Study. <i>Diabetes Care</i> , 2020, 43, 867-874.	8.6	61
13	A Pathophysiologic Primary Prevention Review of Aspirin Administration to Prevent Cardiovascular Thrombosis. <i>Endocrine Practice</i> , 2020, 26, 787-793.	2.1	6
14	Risk Factors for Hearing Impairment in Type 1 Diabetes. <i>Endocrine Practice</i> , 2019, 25, 1243-1254.	2.1	5
15	A Feasible, Simple, Cost-Saving Program to End Cardiovascular Disease in the United States. <i>American Journal of Medicine</i> , 2019, 132, 1365-1367.	1.5	8
16	Prescribing Statins to Reduce Cardiovascular Disease: 10 Common Misconceptions. <i>American Journal of Medicine</i> , 2019, 132, 897-899.	1.5	8
17	Prevention of Statin Overtreatment and Increased Patient Compliance in High-Cardiovascular-Risk Individuals. <i>American Journal of Medicine</i> , 2019, 132, 1123-1125.	1.5	2
18	A Simplified Approach to Reducing Cardiovascular Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6033-6039.	3.6	10

#	ARTICLE	IF	CITATIONS
19	The Rationale for a Different Approach to Preventing Cardiovascular Disease. World Journal of Cardiovascular Diseases, 2019, 09, 489-510.	0.2	2
20	Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. Journal of Lipid Research, 2018, 59, 872-883.	4.2	8
21	Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. Diabetes Care, 2018, 41, 2495-2501.	8.6	27
22	Insulin Timing: A Patient-Centered Approach To Improve Control In Type 1 Diabetes. Endocrine Practice, 2017, 23, 471-478.	2.1	4
23	Abnormal Coronary Artery Calcium Scans in Asymptomatic Patients. American Journal of Medicine, 2017, 130, 394-397.	1.5	8
24	Management of Asymptomatic Patients With Positive Coronary Artery Calcium Scans. Journal of the Endocrine Society, 2017, 1, 588-599.	0.2	5
25	The Role of a Coronary Artery Calcium Scan in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 594-603.	4.4	18
26	The Application of the LDL Principle. World Journal of Cardiovascular Diseases, 2016, 06, 109-125.	0.2	12
27	To Pump or Not to Pump. Diabetes Technology and Therapeutics, 2005, 7, 845-848.	4.4	5
28	Ten pivotal questions about diabetic ketoacidosis. Postgraduate Medicine, 2001, 110, 89-95.	2.0	10
29	Repaglinide Dose Response? A Clinician's Viewpoint. Diabetes Technology and Therapeutics, 1999, 1, 257-258.	4.4	1
30	Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes, Obesity and Metabolism, 1999, 1, 199-206.	4.4	44
31	Challenging Opinions. Postgraduate Medicine, 1988, 83, 72-78.	2.0	0
32	The Role of Catecholamines in Metabolic Acidosis. Novartis Foundation Symposium, 1982, 87, 235-253.	1.1	3
33	THE KETOTIC RATIO (KB/NEFA) IN MAN. Clinical and Experimental Pharmacology and Physiology, 1981, 8, 303-313.	1.9	5
34	The ketotic effects of glucocorticoid and growth hormone in man. Acta Diabetologica Latina, 1980, 17, 161-170.	0.2	5
35	The Temporal Relationship between Endogenously Secreted Stress Hormones and Metabolic Decompensation in Diabetic Man*. Journal of Clinical Endocrinology and Metabolism, 1980, 50, 131-136.	3.6	59